Insulin intranasal - Neurelis
Alternative Names: Insulin Nasal Spray - Neurelis; Shirt pocket insulin - NeurelisLatest Information Update: 21 Jan 2022
At a glance
- Originator Aegis Therapeutics LLC
- Developer Aegis Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (Intranasal, Spray)
- 15 Jul 2014 Insulin intranasal - Aegis Therapeutics is available for licensing in Asia, North America, European Union, Middle East as of 15 Jul 2014. http://aegisthera.com
- 12 Aug 2005 Preclinical trials in Type-2 diabetes mellitus in USA (Intranasal)